SEARCH
GO

DOG OWNER INFORMATION
Dog Owners

How Adequan Canine is Different

How Adequan® Canine (polysulfated glycosaminoglycan) is Different

Only FDA-Approved* Disease Modifying Osteoarthritis Drug (DMOAD)
Adequan® Canine (polysulfated glycosaminoglycan) is the only FDA-approved* DMOAD for dogs in the U.S.

Polysulfated vs. Monosulfated
Adequan® Canine contains multiple sulfur molecules. The larger number of sulfur molecules helps to inhibit the various enzymes that lead to cartilage destruction in arthritis and enhances cartilage metabolism.

Different Active
Adequan® Canine delivers therapeutic drug levels to synovial joints by avoiding the digestive enzymes of the GI tract.

Smallest Molecule
Adequan® Canine’s low molecular weight means it can’t be blocked from the synovial fluid by the synovial membrane.

Proven Efficacy
Several studies** have demonstrated the efficacy of Adequan® Canine in controlling signs of non-infectious degenerative and/or traumatic arthritis.
 

 
 

 
 

* NADA #141-038, Approved by FDA
** Source: Freedom of Information - NADA #141-038; Title: Controlled Field Trial

Product Information
Product Information
Did You Know ...
Did You Know?

About 20% of all adult dogs in the U.S. suffer from canine arthritis.

Adequan® Canine (polysulfated glycosaminoglycan or PSGAG) should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Possible side effects (pain at injection site, diarrhea and abnormal bleeding) were mild, transient and self-limiting. Safety studies of PSGAG in breeding, pregnant or lactating dogs have not been conducted. Click here for full product information.


 
Interwoven VisualPreview: //nov-cont04.novartispharmaceutical.com/us/main/www.milbemite.novartis.us/WORKAREA/UserWorkArea/templatedata/components/opinion_lab.tpl







































Lockedopinion_lab.tpl
New Form Import Edit Upload Submit